Notably, PSD95 expression becomes dysregulated during AD progression, suggesting that its modulation may ameliorate cognitive impairments—providing a theoretical foundation for epigenetic editing as a therapeutic approach. This evidence concerns the gene DLG4 and Alzheimer disease.